Clinical Trial

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-21.
Trial Details
NCT Number NCT06276283
Lead Sponsor Dizal Pharmaceuticals
Conditions Non-small Cell Lung Cancer
Enrollment 60 participants
Start Date 2023-02-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-06-19